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ABSTRACT
INTERFEROME is an open access database of
types I, II and III Interferon regulated genes (http://
www.interferome.org) collected from analysing
expression data sets of cells treated with IFNs.
This database of interferon regulated genes inte-
grates information from high-throughput exper-
iments with annotation, ontology, orthologue
sequences from 37 species, tissue expression pat-
terns and gene regulatory information to enable a
detailed investigation of the molecular mecha-
nisms underlying IFN biology. INTERFEROME fulfils
a need in infection, immunity, development and
cancer research by providing computational tools
to assist in identifying interferon signatures in
gene lists generated by high-throughput expression
technologies, and their potential molecular and bio-
logical consequences.
INTRODUCTION
The interferons (IFNs) are a family of cytokines identiﬁed
more than 50 years ago as potent antiviral proteins. In
addition to antiviral, antibacterial and anti-parasitic
host-defense functions they are now also recognized as
crucial regulators of cell proliferation, diﬀerentiation, sur-
vival and death as well as activators of specialized cell
functions particularly in the immune system (1,2) and
play important roles in infectious and inﬂammatory dis-
eases, autoimmunity and cancer (3). Intriguingly, their
biological properties have led to their use as therapeutics
in certain viral infections such as chronic hepatitis C
(HCV), hepatitis B (HCB) virus infections and in combi-
nation with antiretroviral therapy in AIDS, in haema-
tological cancers and solid tumuors and in multiple
sclerosis (4); but they are targeted for blockade in auto-
immune diseases such as systemic lupus erythematosus (5).
Therefore, understanding the molecular pathways and
genes regulated by IFNs will result in better understanding
of disease mechanisms and eﬀective clinical use of both
IFNs and related cytokines that utilize similar signal
transduction pathways.
There are three types of IFNs, namely types I (IFN a, b,
d, e, z, k, n, t, o), II (IFNg) and III (IFN) (3). Each IFN
type has sequence similarity, signals via speciﬁc cell sur-
face receptor complexes (IFNAR, IFNGR, IFNLR) and
is produced by particular cells in response to speciﬁc sti-
muli (6,7). Despite these diﬀerences, all types of IFNs
mediate their eﬀects by activating multiple signaling path-
ways, some of which are common, including the well-char-
acterized JAK-STAT pathway (8) as well as other
pathways (9). The JAK-STAT signaling events lead to
the activation of transcription factor complexes such as
IFN stimulated gene factor 3 (ISGF3) and homo- or
hetero-dimerized signal transducers and activators of tran-
scription (STAT) molecules, and their subsequent binding
to interferon response elements such as interferon stimu-
lated response element (ISRE), gamma activated sequence
(GAS) and STAT-binding sites in promoters of IRGs,
resulting in the transcriptional activation of many IRGs
(10). The advent of expression proﬁling technology has
enabled us to ascertain a broad picture of gene expression
changes resulting from the action on target cells of cyto-
kines such as IFNs. Some IRGs are well characterized in
relation to speciﬁc functions (e.g. the antiviral Mx pro-
teins, 2, 5-OAS, PKR and RnaseL) (11,12). However,
many IRGs have no known function or functions that
have not been previously associated with IFNs. The chal-
lenge is now to ﬁrstly determine the scope of the genes
regulated by IFNs, and to understand why some, and
not others, are activated or repressed in speciﬁc circum-
stances and relate this to biological outcomes.
In this exercise, we have catalogued IRGs from all pub-
lished reports where cells were treated with an IFN of any
type, and incorporated these into a searchable database
(http://www.interferome.org). The utility of the database
is to enable the reliable identiﬁcation of interferon regu-
lated gene signatures from high-throughput data sets
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identifying regulatory elements and enable comparison of
normal tissue expression of IRGs in human and mouse.
This will have implications for determining hitherto
unknown role of IFNs or IRGs in speciﬁc circumstances
whether regulating homoeostasis or disease pathogenesis
or understanding the basis of patient responses to IFN or
related therapies.
OVERVIEW
The INTERFEROME database enables the identiﬁcation
of interferon regulated genes and integrates IRG-speciﬁc
sequence, annotation and regulatory information. IRGs in
INTERFEROME were collected manually by analysing
in-house IFN microarray data and published microar-
ray/proteomic data sets. In addition, extensive manual
literature mining and searching of regulatory databases,
such as Transcription Regulatory Region Database
(TRRD) (13), was performed to identify previously char-
acterized IRGs.
Sequence and annotation data for IRGs were mined
from public databases such as Ensembl v.49 (14), and
NCBI Entrez Gene (15) using an automated data mining
and integration software pipeline developed in our labora-
tory. The main component of this pipeline is the data
downloader program, which is written in the Perl pro-
gramming language and interacts with the application
programming interfaces (APIs) provided by external data-
bases. It utilizes the list of manually curated IRGs to
extract corresponding sequence and annotation informa-
tion from public databases and ensures that the sequence
and annotation data in INTERFEROME is current. The
sequence data collected includes; genes (59308), amino
acids (79215), putative promoters (79206), 30- and
50-UTR sequences. Annotation includes multiple gene
identiﬁers and gene alias information, gene ontologies
and orthologue information. Orthologues of human and
mouse IRGs were collected from 37 species and will
enable detailed phylogenetic analysis of these proteins.
Basal tissue expression data for human and mouse
IRG were collected from the Novartis Foundation GNF
portal (16). Quality control of sequence data included
BLAST2GO (17) analysis to ensure amino acid sequences
corresponded to relevant IRGs. These diverse data sets
were then processed to generate regulatory information
such as transcription factor binding sites (TFBS), protein
domains and motifs, gene ontologies and normalized
tissue expression.
An example of possible search results is shown in the
screenshots depicted in Figure 1. In addition to identifying
IRG signatures in gene lists we also provide the ability to
identify putative TFBS in proximal promoter regions of
IRGs and the integration of expression information pro-
vides the ability to search for normal tissue expression of
IRGs in 79 human and 61 mouse tissues. We have also
generated BLAST databases of IRG sequences, integrated
with NCBI BLAST software, enabling users to perform
BLAST analysis (15). Addition of data sets and incorpora-
tion of new functionality will be announced in the
INTERFEROME blog (www.interferome.org/blog). As
new data sets are incorporated, INTERFEROME will
grow signiﬁcantly and enable more sophisticated analysis
of IRGs.
DESIGN AND IMPLEMENTATION
Data were collected from in-house IFN-treated microar-
rays and more than 28 publications (18–45) identiﬁed
through literature searches where high-throughput analy-
sis (microarray or proteomic) was performed on cells/tis-
sues treated only with IFNs. The statistical analysis of the
data sets in the relevant publications adhered to currently
accepted methods and standards. Gene lists were analysed
and genes that demonstrated 1.5-fold or more diﬀerential
expression were identiﬁed as IRGs. This included up- and
downregulated genes from 23 human data sets, ﬁve mouse
datasets and single chimp, cow and sheep data sets. There
were 28 type I IFN data sets, 11 type II and three type III
data sets. The subtypes used include type I IFNs such
as (IFNA1a, IFNA1, IFNA2, IFNA2a, IFNA2b, IFN
conA, IFNB, IFNT and IFNE1), type II (IFNG) and
type III (IFNL). Overall 1996 human and 1925 mouse
IRGs were identiﬁed.
INTERFEROME uses an Apache web server, in a
Linux environment and a collection of Perl CGI and
PHP scripts providing the user interface coupled to a
MySQL relational database management system. The
PHP scripts include a tag cloud generator, a Venn visua-
lizer and all the search form pages. Two CGI Perl pro-
grams which generate TFBS graphics [utilizing BioPerl
graphics modules (46)] and hierarchical clustered heat
maps [using Cluster 3.0 and matrix2png (47)] of tissue
expression data provide the other data visualization
methods.
USING INTERFEROME
Searching interferonregulated gene signatures
The main functionality of this database is to enable the
identiﬁcation interferon regulated genes in a gene list gen-
erated from a high-throughput microarray or proteomic
experiment. This ability to detect an interferon signature is
invaluable in identifying interferon regulated pathways
involved in innate immune, inﬂammatory or anti-tumour
responses and will enable the extraction of more mean-
ingful information about the biology associated with a
set of diﬀerentially regulated genes. A mouse or human
gene list of up to 100 genes can be submitted to
INTERFEROME, and provides the option of identifying
either all IRGs or those that are induced by a speciﬁc
interferon type (types I, II or III). The submitted gene
list must be Ensembl IDs as the use of gene names and
gene symbols may result in ambiguities (48). A link is
provided to external gene identiﬁer conversion resources
to enable the conversion of gene identiﬁers (49). When the
list is submitted to the INTERFEROME server, a new
page with identiﬁed IRGs is generated (Supplementary
Figure S1A and B). This page provides information,
such as Ensembl ID, Entrez Gene ID and Gene Symbol,
Nucleic Acids Research, 2009, Vol. 37, Database Issue D853all of which are clickable links that directs the user to the
relevant page in external database resources such as the
Ensembl genome browser, NCBI Gene page or HGNC
gene nomenclature page. In addition, a short description
of each gene and its chromosomal location together with
additional links to external bioinformatic resources such
as iHOP (50), UniProt (51) and the manually curated
VEGA database (52) are provided to enable the collection
Figure 1. The functionality of the INTERFEROME database is summarized in Figure 1, which displays some of the screen captures resulting from
searching the database with a gene list. Its main functionality is the IRG signature page which identiﬁes IRGs that were present in the gene list and
displays associated annotation. In addition INTERFEROME’s expression and promoter analysis capability is highlighted. An example search is
demonstrated in Supplementary Figures.
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of IFN types (I, II or III) that induce the gene is shown
together with the number of data sets (in brackets) in
which a particular gene was diﬀerentially regulated. This
enables the diﬀerentiation of core IRGs (those that are
induced by most IFNs in most situations) from those
that are induced in speciﬁc situations. This page also dis-
plays a tag cloud of all the ontologies associated with the
IRG list where ontologies (obtained from Ensembl and
GO) with higher frequencies are shown in a larger font.
Clicking on an ontology term redirects the user to the gene
ontology organization web page (53) for that particular
term. Finally, a Venn diagram visualization of type I
versus type II is also generated to show the proportional
induction by diﬀerent IFNs. A collection of help pages
oﬀer assistance in using INTERFEROME and an exam-
ple search is available in Supplementary Data.
Searching normaltissue expression of IRGs
The human and mouse expression data sets were down-
loaded from the GNF portal, mapped to IRGs and
expression of each gene was normalized across tissue by
log2 transformation with a mean of 0 and an SD of 1.
When a list of either human or mouse IRGs is submitted,
a results page with a heat map depicting the tissue expres-
sion of the genes in 79 human or 61 mouse tissues is dis-
played (Supplementary Figure S2). Red and blue denote
up and down regulation of gene expression, respectively,
and the intensity of the colour is proportional to the inten-
sity of expression. This heat-map enables the identiﬁcation
of IRGs with tissue-speciﬁc expression. It should be noted
that the heat map reﬂects the tissues where these IRGs are
basally expressed, not after their induction by IFNs.
IRG promoter analysis
INTERFEROME stores more than 274000 TFBS and
enables the visualization of selected TFBS such as ISRE,
STAT, IRF, ICSBP, TATA and NFKB known to be
important in the regulation of IRGs. TFBSs are displayed
in the 1000bp immediately upstream of the transcription
start site (TSS) and includes the 50-UTR. The form also
provides the user with the option of displaying selected
TFBSs within all the known transcripts of a particular
gene (Supplementary Figure S3A and B). Previous analy-
sis of IRGs suggests that core promoters for most
IRGs are located within the ﬁrst 1000bp upstream of
the TSS (54). However,  64% of IRGs collected in
INTERFEROME have ISRE elements within the 10kb
upstream of the TSS. Distal promoter elements that are
beyond the ﬁrst 1000bp may be important for transcrip-
tional regulation of IRGs, thus care should be taken in
interpreting preliminary promoter analysis results and
predictions should be validated by experimental techni-
ques such as chromatin immuno-precipitation (ChIP).
We utilized Transfac Professional version 12.1 to prepro-
cess sequences and store binding sites and their positions
within INTERFEROME. The Transfac database is a col-
lection of position weight matrices for transcription factor
binding sites (55). These matrices are generated from
experimentally derived TFBS (using sequences that are
known to be bound with high aﬃnity by particular tran-
scription factors) derived either by in vitro selection of
tightly bound oligonucleotides (SELEX) or by ChIP or
bandshift experiments that identify speciﬁc transcription
factor–DNA interactions. These matrices summarize how
many sequences have a given nucleotide at a given posi-
tion in the transcription factor binding site. A position
weight matrix (PWM) can be used to deﬁne a position-
speciﬁc scoring matrix (PSSM), whose values are propor-
tional to binding free energies (56). The search form
enables the selection of core and matrix match cut-oﬀs
between 0 and 1. When these match values are closer to
one, only higher stringency TFBS are displayed. The abil-
ity to specify the cut-oﬀ values enables the user to deter-
mine the optimal values necessary to minimize the
identiﬁcation of false-positive and false-negative TFBS.
Orthologue sequencedownload
A search form enabling the submission of a human or
mouse IRG and retrieving its orthologous amino acid
sequences stored in INTERFEROME is provided.
Orthologue sequences are derived from 37 species from
Ensembl version 49. When a human or mouse IRG is
used to search the database a table with a list of ortholo-
gues is displayed and a link to download the sequences
in the FASTA format is provided (Supplementary
Figure S4).
SearchIRG BLAST databases
We have generated IRG protein BLAST databases
for IRG sequences from human, mouse and 37 vertebrate
species, enabling protein or nucleotide BLAST (BLASTP
or BLASTX) analysis to be performed on our sequence
data sets. This functionality will enable other sequences/
novel genes to be searched against IRGs and allow the
identiﬁcation of common domains or novel IRGs. The
BLAST search forms provide the ability to specify
settings and display graphical results similar to NCBI
BLAST (15).
FUTURE DIRECTIONS
As expression, genomic and other sequence information is
updated in external databases, we will reﬂect those
changes in INTERFEROME. In addition as more inter-
feron-treated expression data sets become available, we
hope to add these to INTERFEROME and expand the
IRG data sets. Each additional data set will increase the
reliability and speciﬁcity of the IRG gene set. We propose
to eventually provide normalized expression information
on the IRG data sets and enable IFN subtype, dose, time
and tissue or cell-type-speciﬁc IRG analysis. We will also
provide more comprehensive IRG-speciﬁc regulatory and
interaction information, statistical and computational
methods to analyse cis-regulatory modules, pathway
information, sophisticated data visualization methods
and disease data sets to identify disease-speciﬁc IRG
signatures.
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